ArticleMolecular cancer2019
Correction to: Role of Bruton's tyrosine kinase in B cells and malignancies.
Article in Molecular cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- [Treatment of mast cell-mediated angioedema].Dermatologie (Heidelberg, Germany) · 2026Article
- Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies.Current treatment options in oncology · 2023Review
- Review
- Switch-like activation of Bruton's tyrosine kinase by membrane-mediated dimerization.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
Corrections and comments
- Erratum for
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following publication of the original article [1], the authors reported an error in Table 1.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.